H.C. Wainwright Starts PlasmaTech Bio (PTBI) at Buy, PT $15

H.C. Wainwright initiated coverage on PlasmaTech Bio (NASDAQ: PTBI) with a Buy rating and a price target of $15, suggesting upside of 80% from its previous close. Analyst Andrew S. Fein sees opportunity for its SDF platform in AATD.

"PlasmaTech is set to tackle Alpha-1 Antitrypsin Deficiency (AATD) with a product that already works ... PlasmaTech’s core platform is centered on salt diafiltration (SDF) technology for the isolation of plasma proteins, including (but not limited to) AAT and intravenous immunoglobulin (IVIG). This SDF process offers significant optimization in AAT production yields and costs (~10x), and could easily enable more competitive pricing, and poach market share in this orphan indication (~12K AATD patients on treatment currently)," said Fein.

"Overall, we believe that as the SDF platform begins to move through manufacturing validation and characterization in the next few months, the company is likely to come into the focus of investors and partners alike, with shares continuing on an upwards trajectory reflective of the potential of the AATD orphan market," added the analyst.

For an analyst ratings summary and ratings history on PlasmaTech Bio click here. For more ratings news on PlasmaTech Bio click here.

Shares of PlasmaTech Bio closed at $7.98 yesterday.

You May Also Be Interested In

• Wolfe Research Starts AFLAC (AFL) at Underperform
• CLSA Starts Beike (BEKE) at Outperform (2)
• BMO Capital Starts Perspective Therapeutics Inc (CATX) at Outperform